Analysts at StockNews.com assumed coverage on shares of BIOLASE (NASDAQ:BIOL – Get Rating) in a note issued to investors on Monday. The brokerage set a “sell” rating on the medical technology company’s stock.
Several other research analysts have also weighed in on BIOL. Lake Street Capital reaffirmed a “buy” rating on shares of BIOLASE in a research note on Friday, January 20th. Ascendiant Capital Markets reduced their price target on shares of BIOLASE to $14.00 in a research report on Wednesday, November 16th. Finally, Benchmark reduced their price target on shares of BIOLASE to $7.00 in a research report on Wednesday, November 16th.
BIOLASE Price Performance
BIOLASE stock opened at $0.43 on Monday. The company has a quick ratio of 1.27, a current ratio of 2.46 and a debt-to-equity ratio of 0.92. BIOLASE has a 52-week low of $0.37 and a 52-week high of $9.87. The company has a fifty day simple moving average of $0.53 and a 200-day simple moving average of $1.46. The firm has a market capitalization of $3.30 million, a price-to-earnings ratio of -0.12 and a beta of 1.40.
Institutional Trading of BIOLASE
BIOLASE, Inc is a medical device company, which engages in the developing, manufacturing, marketing and sale of laser systems in dentistry and medicine. It operates through the Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products. The Waterlase systems use a patented combination of water and laser energy to perform procedures using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue.
- Get a free copy of the StockNews.com research report on BIOLASE (BIOL)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.